Detailed Information on Publication Record
2022
Praxe podávání systémových kortikosteroidů kriticky nemocným pacientům s covidem-19 v České republice – dotazníkový průzkum (studie ASAP-C)
MALÁSKA, Jan, Filip KELLER, David CHLEBEK, Jan STAŠEK, Jan HUDEC et. al.Basic information
Original name
Praxe podávání systémových kortikosteroidů kriticky nemocným pacientům s covidem-19 v České republice – dotazníkový průzkum (studie ASAP-C)
Name (in English)
Clinical practise of administration of systemic corticosteroids among critically ill patients with COVID-19 in the Czech Republic: survey (ASAP-C)
Authors
MALÁSKA, Jan (203 Czech Republic, belonging to the institution), Filip KELLER (203 Czech Republic, belonging to the institution), David CHLEBEK (203 Czech Republic, belonging to the institution), Jan STAŠEK (203 Czech Republic, belonging to the institution), Jan HUDEC (203 Czech Republic, belonging to the institution), Tereza PROKOPOVÁ (203 Czech Republic, belonging to the institution), Milan KRATOCHVÍL (703 Slovakia, belonging to the institution), František DUŠKA (203 Czech Republic), J. MÁCA (203 Czech Republic), Kristián BRAT (703 Slovakia, belonging to the institution), Radka ŠTĚPÁNOVÁ (203 Czech Republic, belonging to the institution), Adam SVOBODNÍK (203 Czech Republic, belonging to the institution), Jozef KLUČKA (703 Slovakia, guarantor, belonging to the institution) and Petr ŠTOURAČ (203 Czech Republic, belonging to the institution)
Edition
Anesteziologie a intenzivní medicína, Praha, Česká lékařská společnost J. E. Purkyně, 2022, 1214-2158
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30221 Critical care medicine and Emergency medicine
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 0.100
RIV identification code
RIV/00216224:14110/22:00126013
Organization unit
Faculty of Medicine
UT WoS
000772887900001
Keywords (in Czech)
ARDS; corticosteroids; COVID-19; critical care; survey
Keywords in English
ARDS; corticosteroids; COVID-19; critical care; survey
Tags
International impact, Reviewed
Změněno: 24/2/2023 10:35, Mgr. Tereza Miškechová
V originále
Study objective: Administration of systemic corticosteroids in patients with severe COVID-19 (Coronavirus Disease 2019) has been recommended by World Health Organization (WHO) according to the RECOVERY trial results. However, there is still ongoing debate regarding the evidence supporting the dose, timing, route of administration and type of corticosteroid. This survey aimed to describe the current clinical practice of administration of systemic corticosteroids for patients with COVID-19 within Intensive Care Units (ICU) in Czech Republic. Study design: cross-sectional survey Material and methods: Electronic survey containing 15 questions was sent to the members of Czech Society of Anaesthesiol-ogy, Resuscitation and Intensive Care, Czech Society of Intensive care and Czech Pneumological and Phthisiological Society members. The results were analysed by descriptive statistic methods. Results: The survey fulfilled 233 respondents and 231 answers were eligible for analysis. The most prevalent group was attending physician with completed training in anaesthesiology and intensive care medicine (AIM) (32 %, n = 74). The most prevalent indication for initiation of corticosteroid treatment was oxygen therapy (face mask or nasal cannula) (59,3 %, n = 137) and high-flow nasal oxygen therapy (HFNC) (21,6 %, n = 50). The most preferred corticosteroid was dexamethasone (75,8 %, n = 175) at dose of 8 mg intravenously (i. v.) (48,6 %, n = 85), or dose of 6 mg i. v. (32,0 %, n = 56) followed by methylprednis-olone (25,5 %, n= 59) at dose of 80 mg i. v. (35,6 %, n = 21), and 40 mg i. v. (13,6 %, n = 8), respectively. The preferred duration of therapy was 10 days (dexamethasone 60,6 %, n = 106, methylprednisolone 20,3 %, n = 12). Conclusion: Administration of corticosteroid was dominantly initiated in patients with severe COVID-19 receiving supplemental oxygen. The corticosteroid of first choice was intravenous dexamethasone at dose of 8 mg and 6 mg for 10 days, respectively. © 2022, Czech Medical Association J.E. Purkyne. All rights reserved.
In English
Study objective: Administration of systemic corticosteroids in patients with severe COVID-19 (Coronavirus Disease 2019) has been recommended by World Health Organization (WHO) according to the RECOVERY trial results. However, there is still ongoing debate regarding the evidence supporting the dose, timing, route of administration and type of corticosteroid. This survey aimed to describe the current clinical practice of administration of systemic corticosteroids for patients with COVID-19 within Intensive Care Units (ICU) in Czech Republic. Study design: cross-sectional survey Material and methods: Electronic survey containing 15 questions was sent to the members of Czech Society of Anaesthesiol-ogy, Resuscitation and Intensive Care, Czech Society of Intensive care and Czech Pneumological and Phthisiological Society members. The results were analysed by descriptive statistic methods. Results: The survey fulfilled 233 respondents and 231 answers were eligible for analysis. The most prevalent group was attending physician with completed training in anaesthesiology and intensive care medicine (AIM) (32 %, n = 74). The most prevalent indication for initiation of corticosteroid treatment was oxygen therapy (face mask or nasal cannula) (59,3 %, n = 137) and high-flow nasal oxygen therapy (HFNC) (21,6 %, n = 50). The most preferred corticosteroid was dexamethasone (75,8 %, n = 175) at dose of 8 mg intravenously (i. v.) (48,6 %, n = 85), or dose of 6 mg i. v. (32,0 %, n = 56) followed by methylprednis-olone (25,5 %, n= 59) at dose of 80 mg i. v. (35,6 %, n = 21), and 40 mg i. v. (13,6 %, n = 8), respectively. The preferred duration of therapy was 10 days (dexamethasone 60,6 %, n = 106, methylprednisolone 20,3 %, n = 12). Conclusion: Administration of corticosteroid was dominantly initiated in patients with severe COVID-19 receiving supplemental oxygen. The corticosteroid of first choice was intravenous dexamethasone at dose of 8 mg and 6 mg for 10 days, respectively. © 2022, Czech Medical Association J.E. Purkyne. All rights reserved.
Links
| CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU (CEP code: EF16_013/0001826) |
| ||
| LM2018128, research and development project |
|